Proliferation News and Research

RSS

Novel findings point to new therapeutic approaches for common types of cancer

Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.

18 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Dual role of Notch signalling pathway

Scientists headed by ICREA researcher Marco Mil-n, at the Institute for Research in Biomedicine (IRB Barcelona), reveal a surprising new function of Notch protein that contrasts with the one known to date. Found in the cell membrane, this protein activates a signalling pathway that regulates the expression of genes that make the cell divide, grow, migrate, specialise or die.

16 Mar 2010

Drug-eluting stents offer new hope to patients with critical limb ischemia

In the United States, more than 100,000 amputations are performed each year on individuals with critical limb ischemia, the most severe form of peripheral arterial disease (PAD). The number one priority in treating these patients is to re-establish blood flow to avoid limb amputation.

16 Mar 2010

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

15 Mar 2010

Molecular master switch plays a key role in maturation process of brain cells

About four out of every 10 cells in the brain are so-called oligodendrocytes. These cells produce the all-important myelin that coats nerve tracts, ensuring fast, energy-efficient transmission of nerve impulses.

11 Mar 2010

Keeping pace with emerging health-care advances and tracking progress on achieving learning goals

Physicians would be better prepared for the accelerating rate of scientific discovery - and more in step with the latest in patient-care - if they added an important tool to their medical bags: a plan for how to keep pace with emerging health-care advances.

9 Mar 2010

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.

9 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

mtm laboratories launches CINtec PLUS screening system for cervical cancer

mtm laboratories, a privately held diagnostics company today announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.

8 Mar 2010

Endothelial cells can produce copious amounts of adult stem cells: Study

In a leap toward making stem cell therapy widely available, researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College have discovered that endothelial cells, the most basic building blocks of the vascular system, produce growth factors that can grow copious amounts of adult stem cells and their progeny over the course of weeks.

5 Mar 2010

Signaling mechanisms responsible for HGF-induced CCA invasiveness: More insight

Cholangiocarcinoma (CCA), a bile duct cancer, is one of the major cancers in Northeast Thailand. This cancer is difficult to diagnose and has high metastatic and mortality rates. Overexpression of Met, a hepatocyte growth factor (HGF) receptor, has frequently been found in CCA and is correlated with progression of this type of cancer.

5 Mar 2010

OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher M. Tong, The Ohio State University, will present a poster of a study titled "Epithelial-to-Endothelial Transition: An Epithelial Phenotypic Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression."

5 Mar 2010

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Kyto Biopharma Inc., is pleased to announce that it has signed a licensing agreement with the Research Foundation of the State University of New York. The licensing agreement grants Kyto patent rights to the Transcobalamin (Vitamin B12) Receptor and to an additional broad group of other patents which are critical to Kyto’s research and development strategy for the treatment of cancer.

5 Mar 2010

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

Exposure to blue-violet light may enhance cell growth in wound sites

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher C. Millan (U.S. Army Dental Corps, Martinez, Georgia) will present a poster of a study titled "A Novel In Vitro Model for Light-Induced Wound Healing."

4 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Sigma-Aldrich® today unveiled its new Sigma® Life Science brand and website platform, designed to elevate the Company's current focus on biology and provide a single destination where researchers can access deep biological knowledge and market-leading products and technologies.

2 Mar 2010

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

OncoGenex Pharmaceuticals, Inc., announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as custirsen (OGX-011) that is designed to knock down treatment resistance in the cells and enhance the effectiveness of cancer therapies.

1 Mar 2010

Proliferation News and Research

Novel findings point to new therapeutic approaches for common types of cancer

Key cellular defect in protein synthesis can lead to cancer susceptibility

Dual role of Notch signalling pathway

Drug-eluting stents offer new hope to patients with critical limb ischemia

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Molecular master switch plays a key role in maturation process of brain cells

Keeping pace with emerging health-care advances and tracking progress on achieving learning goals

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

Rexahn Pharmaceuticals granted Japanese patent for Archexin

mtm laboratories launches CINtec PLUS screening system for cervical cancer

Endothelial cells can produce copious amounts of adult stem cells: Study

Signaling mechanisms responsible for HGF-induced CCA invasiveness: More insight

OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Exposure to blue-violet light may enhance cell growth in wound sites

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News